Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer

Trial StartcadonilimabnivolumabPositive

AI Analysis

Summary

Akeso announced the first patient enrollment in COMPASSION-37, a global Phase III trial comparing cadonilimab to nivolumab in first-line gastric cancer treatment. The trial is evaluating Akeso's first-in-class PD-1/CTLA-4 bispecific antibody in a head-to-head comparison.

Clinical Trial Data

Phase

Phase III

Outcome Details

First patient enrolled in COMPASSION-37 (AK104-311), a global Phase III head-to-head trial

Importance:6/10

Sentiment:

0.60

Phase III trialGastric cancerImmunotherapyPD-1/CTLA-4Clinical development

Related Companies

$GBCYD $TRAX

Read the original article

Published by PR Newswire Pharma on September 28, 2026 2:05 AM

Read Original